Overview

Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators hypothesize that Klacid modified release (MR) shortens symptom recovery time in Thai patients with upper or lower respiratory tract infections.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Abbott
Treatments:
Clarithromycin
Criteria
Inclusion Criteria:

- Patients with upper or lower respiratory tract infection.

- Patient is male or female ≥ 18 years of age.

Exclusion Criteria:

- Known hypersensitivity to or previously intolerant of macrolides.

- Illness severe enough to warrant hospitalization or parenteral therapy.

- Concomitant use of any of the following medications:

- Drugs metabolized by CYP3A isozyme: alprazolam, astemizole, carbamazepine,
cilostazol, cisapride, cyclosporin, disopyramide, ergot alkaloids, lovastatin,
methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin),
pimozide, quinidine, rifabutin, sildenafil, simvastatin, tacrolimus, terfenadine,
triazolam and vinblastine.

- Drugs metabolized by other isozymes within CYP450 system: phenytoin, theophylline
and valproate.

- Colchicine

- Digoxin

- Some antiretrovirals: zidovudine and ritonavir.

- Severe immunodeficiency and chronic disease conditions.

- Renal or hepatic impairment.